Results
1
Companies which are more than 50% undervalued based on analyst price target.
1 companies
Oryzon Genomics
Market Cap: €245.2m
A clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders.
ORY
€3.11
7D
-6.0%
1Y
72.8%